A5103263342- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Nanoparticles: synthesis and applications
- Animal Virus Infections Studies
- Viral Infections and Immunology Research
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Heavy metals in environment
- Immunotherapy and Immune Responses
- Geochemistry and Elemental Analysis
- SARS-CoV-2 detection and testing
First Affiliated Hospital of Guangzhou Medical University
2024-2025
State Key Laboratory of Respiratory Disease
2024-2025
Guangzhou Medical University
2024-2025
South China Normal University
2024
Nanchang University
2023
Omicron, as the emerging variant with enhanced vaccine tolerance, has sharply disrupted most therapeutic antibodies. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to subgenus Sarbecovirus, members of which share high sequence similarity. Herein, we report one sarbecovirus antibody, 5817, broad-spectrum neutralization capacity against SARS-CoV-2 variants concern (VOCs) and SARS-CoV, well related bat pangolin viruses. 5817 can hardly compete six classes...
Neutralizing antibody titers have been shown to correlate with immune protection against COVID-19 and can be used estimate vaccine effectiveness. Numerous studies explored the relationship between neutralizing antibodies protection. However, there remains a lack of quantitative data directly assessing minimum effective protective titer in vivo. In this study, we utilized eight cohorts participants diverse backgrounds for evaluation response. To precisely assess lower threshold required...
Abstract Research on virus/receptor interactions has uncovered various mechanisms of antibody‐mediated neutralization against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). However, understanding by antibodies targeting the silent face, which recognize epitopes glycan shields, remains limited, and their potential protective efficacy in vivo is not well understood. This study describes a face neutralizing antibody, 3711, targets non‐supersite N‐terminal domain (NTD) spike...